Trial
NCT02177812
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Leukaemia, Myelocytic, Acute
Intervention
GSK2879552
Why stopped
The risk benefit in relapsed refractory AML does not favor continuation of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-28